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Background: Peroxisome proliferator activated receptor alpha (PPARα) ameliorates ethanol induced hepatic
steatohepatitis. However, its role in alcoholic liver fibrosis has not been fully clarified. The aim of this study was to
elucidate the effect and the molecular basis of PPARα in ethanol induced liver fibrosis in mice.
Methods: C57BL/6J mice were fed with 4% ethanol-containing Lieber-DeCarli liquid diet for eight weeks, and
intraperitoneal injected with 5% carbon tetrachloride (CCl4) for the last four weeks to induce alcoholic liver fibrosis.
PPARα agonist WY14643 was administered to mice during the last couple of weeks. The effects of PPARα induction
on liver histology, activation of hepatic stellate cells (HSCs), as well as hepatic expression of inflammatory and
fibrogenic factors were assessed.
Results: The ethanol plus CCl4 treated mice exhibited progressive liver injury including piecemeal necrosis of
hepatocytes, severe inflammatory cells infiltration and bridging fibrosis. This was accompanied by down-regulated
hepatic expression of PPARα and the protective cytokines adiponectin, heme oxygenase-1 and interleukin-10.
Additionally, up-regulation of the proinflammatory cytokine tumor necrosis factor-alpha, as well as the
profibrogenic genes osteopontin, transforming growth factor-beta 1, visfatin, phosphatidylinositol 3-kinase, matrix
metalloproteinase-2 (MMP-2) and MMP-9 was observed. WY14643 treatment restored expression of cytokines
altered by ethanol plus CCl4 treatment and concomitantly ameliorated the liver injury.
Conclusions: The present study provides evidence for the protective role of PPARα induction in ameliorating
ethanol mediated fibrosis through mediation of inflammatory and fibrogenic factors.
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Alcoholic liver fibrosis is a severe form of alcoholic liver
disease (ALD), which may progress to liver cirrhosis and
hepatocellular carcinoma. Hepatic ethanol metabolism
leads to the release of reactive oxygen species (ROS) and
generation of lipid peroxidation products [1], which directly
damage hepatocyte membranes and organelles, leading to
inflammatory responses [2], including activation of Kupffer
cells and subsequent release of proinflammatory and pro-
fibrogenic cytokines, such as tumor necrosis factor alpha* Correspondence: nanyuemin@163.com
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reproduction in any medium, provided the or(TNF-α) and transforming growth factor beta 1 (TGF-β1)
[3]. TGF-β1 plays a crucial role in the development of
hepatic fibrosis [4], through transdifferentiating quiescent
hepatic stellate cells (HSCs) into myofibroblast-like cells,
suppressing degradation and stimulating production of
extracellular matrix (ECM). It is of great practical signifi-
cance to identify potent pharmacological agents which
target the activated HSCs and fibrogenic mediators to pro-
tect against ethanol-related liver fibrosis.
Previously, we demonstrated the role of nuclear tran-
scription factor peroxisome proliferators activated recep-
tor alpha (PPARα) in lipid homeostasis and modulation of
inflammatory responses in alcoholic steatohepatitis [5]. In-
duction of PPARα significantly ameliorated the severity of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lipid metabolism and inflammation related genes. How-
ever, the role of PPARα in alcoholic liver fibrosis, the more
severe form of ALD, remains largely unknown. In the
present study, the underlying molecular mechanisms of
ethanol induced hepatic fibrosis and the effect of PPARα
in the pathogenesis of alcohol-induced liver fibrosis were
elucidated.
Results
Activation of PPARα by WY14643 lowered the serum
alanine aminotransferase (ALT) and aspartic transaminase
(AST) levels in mice under ethanol plus carbon
tetrachloride (CCl4) treatment
As shown in Figure 1, mice treated with ethanol or etha-
nol plus CCl4 showed significantly higher serum ALT and
AST levels compared with the control mice, (P<0.01), es-
pecially in ethanol plus CCl4 group, which showed more
pronounced liver injury. However, a significant reduction
of serum ALT and AST levels (P<0.01) was noticed after
WY14643 treatment.
Reversal of liver injury induced by ethanol and CCl4 after
activation of PPARα
Moderate macrosteatosis and mild inflammatory infiltra-
tion were exhibited in the liver sections of mice fed with
ethanol liquid diet. Notably, pronounced inflammatory
infiltration, piecemeal hepatocyte necrosis, perisinusoidal
and bridging fibrosis were found in the liver sections of
mice administrated with ethanol plus CCl4. Treatment
with PPARα agonist WY14643 significantly ameliorated
the liver injury (Figure 2A, 2B and 2D).
Effect of PPARα induction on activation of HSCs in
ethanol and CCl4 induced liver fibrosis in mice
We evaluated the role of PPARα in the development
of liver fibrosis by assessing the hepatic expression of
α-smooth muscle actin (α-SMA), a well-known marker
of activated HSCs. Compared with control or ethanol
treated mice, markedly increased α-SMA expression inFigure 1 Effects of WY14643 on serum alanine aminotransferase (ALT
Serum AST levels. *P<0.01, vs. control group; #P<0.01, vs. ethanol group; $P<the activated HSCs and fibrotic areas of liver sections was
observed in ethanol plus CCl4 treated mice, which was
significantly blunted by WY14643 treatment (Figure 2C).
Hepatic PPARα expression in mice fed with ethanol liquid
diet and/or intraperitoneally injected with CCl4, and
treated with WY14643
Hepatic PPARα mRNA and protein expressions were
down-regulated by ethanol treatment, and further de-
creased by ethanol plus CCl4 administration. WY14643
administration restored the expression level of PPARα in
ethanol plus CCl4 treated mice (Figure 3).
Induction of PPARα regulated hepatic expression of
inflammatory cytokines
To explore the mechanisms of PPARα activation in allevi-
ating ethanol related liver injury, we assessed hepatic
mRNA expression levels of inflammatory cytokines. Etha-
nol treatment increased hepatic expression of the proin-
flammatory factor tumor necrosis factor-alpha (TNF-α),
and reduced expression of the anti-inflammatory factor
interleukin-10 (IL-10). Co-administration of ethanol and
CCl4 showed an obviously additive effect in altering TNF-α
and IL-10 expression. This action was significantly blunted
by WY14643 treatment (P<0.01) (Figure 4).
Activation of PPARα suppressed hepatic expression of
profibrogenic cytokines
To seek an explanation for the ameliorated liver fibrosis
under WY14643 administration, hepatic expression
levels of profibrogenic genes were investigated. As shown
in Figure 5, ethanol treatment increased hepatic osteopon-
tin (OPN), transforming growth factor-beta 1 (TGF-β1),
visfatin, phosphatidylinositol 3-kinase (PI3K), matrix
metalloproteinase-2 (MMP-2), MMP-9 mRNA and
protein expression (P<0.05). A further up-regulation
of these genes was noted in mice treated with ethanol
plus CCl4 (P<0.05). WY14643 suppressed OPN, TGF-β1,
visfatin, PI3K, MMP-2 and MMP-9 mRNA and) and aspartic transaminase (AST) levels. (A) Serum ALT levels. (B)
0.01, vs. ethanol+CCl4 group. CCl4, carbon tetrachloride; WY, WY14643.
Figure 2 Histopathological changes in liver sections of mice under various treatment conditions. (A) Hematoxylin and eosin stained liver
sections from the mice (original magnification, × 200), (B) Masson stained liver sections from the mice (original magnification, × 200), (C) Hepatic
expression of alpha-smooth muscle actin (α-SMA) protein determined by immunohistochemistry (original magnification, × 200) (D) Scores for
hepatic steatosis, inflammation and fibrosis. *P<0.05, **P<0.01, ***P<0.001, vs. control group; #P<0.001, vs. ethanol group; $P<0.01, vs. ethanol+CCl4
group. CCl4, carbon tetrachloride; WY, WY14643.
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(P<0.01).Activation of PPARα enhanced hepatic expression of anti-
fibrotic cytokines
Hepatic expression of anti-fibrotic genes was also assessed
to clarify the underlying mechanism of the protective role
of PPARα. Ethanol treatment reduced adiponectin mRNA
and protein expression (P<0.01), but increased heme
oxygenase-1 (HO-1) expression (P<0.05). Ethanol plus
CCl4 treatment further decreased adiponectin and
increased HO-1 expression (P<0.05). WY14643 prom-
inently up-regulated adiponectin and HO-1 (P<0.01and P<0.001) mRNA and protein expression in ethanol
plus CCl4 treated mice (Figure 6).
Discussion
Alcoholic liver fibrosis is characterized by severe liver in-
flammatory response and fibrosis owing to augmented
oxidative stress as well as generation of cell-toxic and pro-
fibrogenic ethanol metabolites, such as acetaldehyde and
lipid oxidation products, which cause hepatocellular injury
and activation of HSCs. A representative animal model of
alcoholic liver fibrosis should reflect the characteristic
metabolic changes and typical histological lesions of pro-
gressive fibrosing steatohepatitis, enabling ascertainment
of pathogenesis and evaluation of drug therapy. In the
Figure 3 Effect of WY14643 on hepatic expression of peroxisome proliferators activated receptor alpha (PPARα). (A) Expression level of
PPARα mRNA and (B) protein in various treatment groups. *P<0.01, vs. control group; #P<0.05, ##P<0.001, vs. ethanol group; $P<0.001, vs. ethanol+CCl4
group. CCl4, carbon tetrachloride; WY, WY14643.
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coholic liver fibrosis by feeding C57BL/6J mice with 4%
ethanol-containing Lieber-DeCarli liquid diet for 8 weeks
and combined with 5% CCl4 intraperitoneal injection for
the last 4 weeks. After the combined administration, the
mice rapidly and consistently developed alcoholic liver
fibrosis manifested histologically by pronounced inflam-
matory infiltration, piecemeal hepatocellular necrosis, peri-
sinusoidal and bridging fibrosis, together with enhanced
hepatic expression of α-SMA, as well as significantly ele-
vated serum ALT and AST levels. Conversely, ethanol
treatment caused moderate macrosteatosis and mild in-
flammatory infiltration in the mice liver. These findings
indicated that an alcoholic liver fibrosis model could be
established rapidly and successfully by feeding mice etha-
nol liquid diet combined with a small amount of CCl4
intraperitoneal injection. Ethanol was the key mediator to
induce liver injury, whilst CCl4 accelerated the progressionFigure 4 Effect of peroxisome proliferators activated receptor alpha (
(A) Expression level of tumor necrosis factor-alpha (TNF-α) and (B) interleuk
group; #P<0.01, vs. ethanol group; $P<0.01, vs. ethanol+CCl4 group. CCl4, caof liver injury by increasing lipid accumulation [6,7] and
enhancing oxidative stress [8,9].
With the progression of liver fibrosis, hepatic PPARα ex-
pression was reduced, suggesting that abnormal expression
and/or dysfunction of PPARα might be involved in the de-
velopment of ethanol plus CCl4 induced liver injury. We
further demonstrated that induction of PPARα by specific
agonist WY14643 administration for two weeks promin-
ently attenuated liver injury, as evidenced by decreased
serum ALT and AST levels, diminished inflammatory re-
sponse, reduced collagen deposition, as well as suppressed
activation of HSCs. These results indicated that PPARα
played an important protective role in the progression of
alcoholic liver fibrosis.
Oxidative stress and release of inflammatory cytokines
induced by ethanol metabolism can evoke the activation
of HSCs. Once activated, HSCs migrate to the site of liver
injury and secrete excessive ECM [10], which is the pivotalPPARα) induction on hepatic expression of inflammatory factors.
in-10 (IL-10) mRNA in various treatment groups. *P<0.01, vs. control
rbon tetrachloride; WY, WY14643.
Figure 5 Effect of peroxisome proliferators activated receptor alpha (PPARα) induction on hepatic expression of profibrotic factors.
(A1) Expression level of osteopontin (OPN) mRNA and (A2) protein; (B1) Expression level of transforming growth factor-beta 1 (TGF-β1) mRNA
and (B2) protein; (C1) Expression level of visfatin mRNA and (C2) protein; (D1) Expression level of phosphatidylinositol 3-kinase (PI3K) mRNA and
(D2) protein; (E1) Expression level of matrix metalloproteinase-2 (MMP-2) mRNA and (E2) protein; (F1) Expression level of MMP-9 mRNA and (F2)
protein in various treatment groups. *P<0.05, **P<0.01, ***P<0.001, vs. control group; #P<0.05, ##P<0.01, vs. ethanol group; $P<0.01, $$P<0.001, vs.
ethanol+CCl4 group. CCl4, ccarbon tetrachloride; WY, WY14643.
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of proinflammatory and profibrogenic factors are involved
in controlling the activation and proliferation of HSCs.
TNF-α, a pivotal inflammatory cytokine, exerts a profibro-
genic function by inducing HSCs activation and inhibiting
HSCs apoptosis [11]. We found that hepatic expression of
TNF-α was increased in mice fed with ethanol liquid diet
and intraperitoneally injected with CCl4, which was signifi-
cantly reduced by WY14643 treatment. In addition, we
demonstrated that hepatic expression of OPN and TGF-β1
was up-regulated by ethanol with or without CCl4treatment and restored by WY14643 administration. OPN
is a chemoattractant molecule engaged in the hepatic in-
flammatory response by promoting neutrophil infiltration
in the liver [12]. As a biomarker of fibrosis [13], OPN can
bind to integrin on the surface of HSCs to drive the fibro-
genic response by regulating collagen I deposition [14,15].
TGF-β1 is the most critical profibrogenic factor involved
in the initiation and maintenance of liver fibrogenesis
[4,16]. It was reported that TGF-β1 increased expression of
OPN [17], which in turn up-regulated TGF-β1 expression
and activated HSCs through TGF-β1/Smad pathway [18],
Figure 6 Effect of peroxisome proliferators activated receptor alpha (PPARα) induction on hepatic protein expression of anti-fibrotic
factors. (A1) Expression level of adiponectin mRNA and (A2) protein; (B1) Expression level of heme oxygenase-1 (HO-1) mRNA and (B2) protein
in various treatment groups. *P<0.05, **P<0.01, ***P<0.001, vs. control group; #P<0.05, ##P<0.01, vs. ethanol group; $P<0.01, $$P<0.001, vs. ethanol
+CCl4 group. CCl4, carbon tetrachloride; WY, WY14643.
Nan et al. Lipids in Health and Disease 2013, 12:11 Page 6 of 10
http://www.lipidworld.com/content/12/1/11forming a vicious circle promoting liver fibrogenesis. Thus,
the role of PPARα induction in alleviating alcoholic fibrotic
hepatitis was possibly related to the down-regulation of
TNF-α, OPN and TGF-β1, as well as the subsequent sup-
pression of inflammatory response and fibrogenesis.
To further clarify the mechanism by which PPARα alle-
viated ethanol mediated liver fibrosis in mice, hepatic ex-
pression of visfatin, a novel identified adipocytokine, was
assessed. It was considered as a proinflammatory cytokine
and could be up-regulated by TNF-α [19,20]. In the livers
of ethanol plus CCl4 treated mice, visfatin expression was
markedly up-regulated, accompanied with increased hep-
atic expression of PI3K, MMP-2 and MMP-9. In accord
with our results, one study reported that visfatin induced
MMP-2 and MMP-9 production in endothelial cells,
which was mediated by the PI3K signaling pathway [21].
MMP-2, secreted by activated HSCs, is considered a profi-
brotic mediator exerting proliferation and migration of
HSCs [22,23], and can be up-regulated by TGF-β and/or
ROS stimulation [24,25]. Meanwhile, MMP-9 can stimu-
late HSCs activation and up-regulate TGF-β1 expression
[26,27], which in turn induces MMP-9 expression through
PI3K/Akt/nuclear factor-kappa B signaling pathway [28].
We demonstrated that PPARα agonist significantly
repressed hepatic expression of visfatin, and conse-
quently reduced PI3K, MMP-2 and MMP-9expression, thus suppressing the progression of etha-
nol mediated liver fibrosis.
We considered whether protective cytokines mediated
the effect of PPARα in alleviating ethanol induced liver
injury. Indeed, we found that reduced hepatic expres-
sion of adiponectin in alcoholic liver fibrosis mice was
restored by WY14643 treatment. Adiponectin exerts its
anti-inflammatory property through suppressing TNF-α
production and secretion [29], and alleviates hepatic
fibrosis by maintaining quiescence of HSCs and induct-
ing apoptosis of activated HSCs [30-32]. Adiponectin
induces expression of several other protective mediators,
and an IL-10/HO-1 pathway is involved in the anti-
inflammatory effects of adiponectin [33]. IL-10 inhibits
intrahepatic fibrogenesis by suppressing production of col-
lagen I [34,35], down-regulating expression of profibro-
genic factors TGF-β1, MMP-9 and TNF-α [36-38], and
promoting apoptosis of activated HSCs [39]. In addition,
IL-10 up-regulates HO-1 expression through the p38
mitogen-activated protein kinase pathway [40,41]. HO-1
acts as an anti-oxidant and anti-fibrogenic protein in the
liver. It was reported that induction of HO-1 suppressed
oxidative stress and HSCs activation, thus inhibiting liver
fibrogenesis in nutritional fibrotic steatohepatitis in mice
[42]. In keeping with this observation, we found that IL-10
and HO-1 expression was up-regulated by WY14643,




PPARα 149 bp F 5’-GATGTCACACAATGCAATTCG -3’
R 5’-GGTAGGCTTCGTGGATTCTCT -3’
TNF-α 300 bp F 5’-GGCAGGTCTACTTTGGAGTCATTGC-3’
R 5’-ACATTCGAGGCTCCAGTGAATTCGG-3’
IL-10 142bp F 5’-TGCTGCCTGCTCTTACTGAC-3’
R 5’-AGAAAGTCTTCACCTGGCTGA-3’
OPN 121 bp F 5’-GGTGATAGCTTGGCTTATGGAC-3’
R 5’-CCTTAGACTCACCGCTCTTCAT-3’
TGF-β1 272 bp F 5’-CAACGCCATCTATGAGAAAACC-3’
R 5’ -ACTGCCGTACAACTCCAGTGAC-3’
visfatin 172 bp F 5’- GGAAAGACCATGAGAAAGATGC-3’
R 5’-CTGATGATTAGTGGTGCCTCTG-3’
PI3K 198 bp F 5’- GCACGGCGATTACACTCTTAC-3’
R 5’-TTGGACACTGGGTAGAGCAAC-3’
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plus CCl4 administration. Therefore, the protective role of
PPARα induction against liver inflammation and fibrosis
was mediated by up-regulating anti-inflammatory and
anti-fibrogenic cytokines.
Conclusions
In summary, the present study demonstrated a protect-
ive role of PPARα induction in experimental alcoholic
liver fibrosis through down-regulating the proinflamma-
tory and profibrogenic factors TNF-α, OPN, TGF-β1,
visfatin, PI3K, MMP-2 and MMP-9, and up-regulating
the tissue-protective cytokines adiponectin, IL-10 and
HO-1. Consequently, PPARα agonist administration




Eight-week-old male C57BL/6J mice were bred and
housed as previously described [5]. The mice were ran-
domly divided into 4 groups (6 mice per group): control
group, mice fed with non-alcoholic control liquid diet
(TROPHIC Animal Feed High-tech Co., Ltd., Nantong,
China); ethanol group, mice fed with 4% ethanol-
containing Lieber-DeCarli liquid diet (TROPHIC);
ethanol plus CCl4 (ethanol+CCl4) group, mice fed with
ethanol liquid diet, and received 5% CCl4 (Sinopharm
Chemical Reagent Co., Ltd, Shanghai, China) dissolved in
olive oil (Sinopharm) intraperitoneal injection, 2 ml/kg
body weight, twice a week; ethanol plus CCl4 and
WY14643 (ethanol+CCl4+WY) group, mice fed with etha-
nol liquid diet with WY14643 (50 mg/kg/d, Cayman
Chemical, Ann Arbor, MI, CA), and administrated with
5% CCl4 intraperitoneal injection (Figure 7). The dur-
ation of the experiment was 8 weeks. The CCl4 intraper-
itoneal injection was administrated in the last 4 weeks,
while PPARα agonist WY14643 was administrated in theFigure 7 Schematic representation of the experimental
schedule for the model induction and the pharmacological
invention. CCl4, carbon tetrachloride; WY, WY14643.last 2 weeks. Animals were sacrificed after overnight fast-
ing at the end of experiment. Blood samples were col-
lected from femoral artery for biochemical analysis. Livers
were weighed, and fixed in 10% formalin for histological
analysis, or snap-frozen in lipid nitrogen followed by stor-
age at −80°C in a freezer until required. All the protocols
and procedures were performed following the Guidelines
of the Hebei Committee for Care and Use of Laboratory
Animals and were approved by the Animal Experimenta-
tion Ethics Committee of the Hebei Medical University.Biochemical analyses
Serum ALT and AST levels were measured by the enzym-
atic method using an automatic biochemical analyzer
(Olympus UA2700, Japan) according to the manufacturer’s
instructions.MMP-2 203 bp F 5’- TTGTGCTGAAAGATACCCTCAA-3’
R 5’-CAGGTCAGGTGTGTAACCAATG-3’
MMP-9 242 bp F 5’-TGAATCAGCTGGCTTTTGTG-3’
R 5’-GTGGATAGCTCGGTGGTGTT-3’
adiponectin 202 bp F 5’-CCAGTATCAGGAAAAGAATGTGG-3’
R 5’-TGGTGTATGGGCTATGGGTAGT-3’
HO-1 427 bp F 5’-AACAAGCAGAACCCAGTCTATG-3’
R 5’-TGAGCAGGAAGGCGTCTTA-3’
GAPDH 233 bp F 5’-GGTGAAGGTCGGTGTGAACG-3’
R 5’-CTCGCTCCTGGAAGATGGTG-3’
Abbreviations: PPARα, peroxisome proliferator activated receptor alpha; TNF-α,
tumor necrosis factor-alpha; IL-10, interleukin-10; OPN, osteopontin; TGF-β1,
transforming growth factor-beta 1; PI3K, phosphatidylinositol 3-kinase; MMP-2,
matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9; HO-1, heme
oxygenase-1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Haematoxylin and eosin stained paraffin-embedded
liver sections (5 μm thick) were scored as follows: (a)
degree of steatosis (0 ≤ 10%, 1 = 10-33%, 2 = 33-66%,
3 ≥ 66%); (b) degree of necroinflammation (0 = none,
1 = mild, 2 = moderate, 3 = severe); (c) stage of fibro-
sis (0 = no fibrosis, 1 = mild/moderate zone 3 perisi-
nusoidal fibrosis or portal fibrosis only, 2 = zone 3 and
portal/periportal fibrosis, 3 = bridging fibrosis, and 4 = cir-
rhosis) in accordance with a scoring system for ALD
designed by Dominguez et al. [43] and the Chinese Guide-
lines for the diagnosis and management of alcoholic liver
disease [44].
Immunohistochemistry
Immunostaining was performed in paraffin-embedded
liver sections using the specific antibody and an avidin-
biotin complex (ABC) immunoperoxidase method. Briefly,
after antigen repair, the primary specific antibody for
α-SMA (dilution 1: 200) (Santa Cruz Biotechnology,
Santa Cruz, CA) was applied. The primary antibody
was omitted and phosphate buffered saline was used
as the negative control. After extensive rinsing, the
biotinylated secondary antibody and ABC complex/
horseradish peroxidase were applied. Peroxidase activ-
ity was visualized by applying diaminobenzidine (Santa
Cruz Biotechnology) to the sections, which were then
counter-stained with hematoxylin. Quantitative ana-
lysis of α-SMA stained liver sections (200 fold) was
performed by morphometric analysis: the average area
density (areas of positive cells/total areas × 100%) in
each section was estimated.Quantitative real-time reverse transcription polymerase
chain reaction (qRT-PCR) analysis of hepatic mRNA
expression
Total RNA was isolated from liver tissues using Trizol
Reagent (Tiangen Biotech, Beijing, China) according to
the manufacturer’s instructions. The hepatic mRNA
levels of PPARα, TNF-α, OPN, TGF-β1, visfatin, PI3K,
MMP-2, MMP-9, adiponectin, IL-10 and HO-1 were
determined by qRT-PCR using the ABI PRISM 7500
sequence detection system (Applied Biosystems, Foster,
CA) with SYBR Green Reagent (Tiangen Biotech). Expres-
sion levels of the target genes were normalized against an
endogenous reference gene glyceraldehydes 3-phosphate
dehydrogenase (GAPDH). The specific primer sequen-
ces were listed in Table 1. All data were obtained using
Sequence Detector Software (Applied Biosystems).
Western blot analysis of hepatic protein expression
Total protein was extracted and concentration was mea-
sured by the Bradford method (DC protein assay; Bio-Rad,Hercules, CA). Equal amounts of protein (100 ìg/well)
were loaded onto 12% SDS-PAGE for each sample and
proteins were transferred onto equilibrated polyvinylidene
difluoride membranes (Millipore Corporation, Billerica,
MA) by electroblotting. The membranes were incubated
with primary antibodies of PPARα, OPN, TGF-β1, visfatin,
PI3K, MMP-2, MMP-9, adiponectin, HO-1 and â-actin
(Santa Cruz Biotechnology), respectively, overnight at 4°C.
Membranes were further incubated with secondary
antibody for 1h at room temperature. Proteins were
detected by enhanced chemiluminescence (Santa Cruz
Biotechnology). The amount of protein expression was
corrected by that of â-actin in the same sample and the
bands were quantified by scanning densitometry using
the digital Kodak Gel Logic 200 (Carestream Molecular
Imaging, Woodbridge, CT).
Statistical analysis
All data are expressed as mean ± standard deviation
(SD). Statistical analysis on the data was performed
by one-way analysis of variance (ANOVA) or Kruskal-
Wallis H test, with the least significant difference-t
(LSD-t) test or Mann–Whitney u test for post-hoc com-
parison using SPSS 13.0 (v. 13.0; SPSS Inc., Chicago, IL),
and P-value below 0.05 was considered significant.
Abbreviations
PPARα: Peroxisome proliferator activated receptor alpha; CCl4: Carbon
tetrachloride; HSCs: Hepatic stellate cells; MMP-2: Matrix metalloproteinase-2;
MMP-9: Matrix metalloproteinase-9; ALD: Alcoholic liver disease; TNF-α: Tumor
necrosis factor-alpha; TGF-β1: Transforming growth factor-beta1; ALT: Alanine
aminotransferase; AST: Aspartic transaminase; α-SMA: Alpha-smooth muscle
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dehydrogenase.
Competing interests
The authors report no conflicts of interest. The authors alone are responsible
for the content and writing of the paper.
Authors’ contributions
YN designed the research; LK, WR, RW, JD, WL, SZ, YZ, WW, HD and YL
performed the experiments; LK and YN analyzed data; YN, LK and JY wrote
the paper. All authors read and approved the final manuscript.
Acknowledgments
This work was funded by Wang Bao-en Foundation of Hepatic Fibrosis,
Chinese foundation for hepatitis prevention and control, No. 2009009.
Author details
1Department of Traditional and Western Medical Hepatology, Third Hospital
of Hebei Medical University, Shijiazhuang, China. 2Institute of Digestive
Disease and Department of Medicine and Therapeutics, Li Ka Shing Institute
of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong
Kong.
Received: 30 December 2012 Accepted: 31 January 2013
Published: 6 February 2013
References
1. Cederbaum AI, Lu Y, Wu D: Role of oxidative stress in alcohol-induced
liver injury. Arch Toxicol 2009, 83:519–548.
Nan et al. Lipids in Health and Disease 2013, 12:11 Page 9 of 10
http://www.lipidworld.com/content/12/1/112. Lieber CS: Ethanol metabolism, cirrhosis and alcoholism. Clin Chim Acta
1997, 257:59–84.
3. Cubero FJ, Nieto N: Ethanol and arachidonic acid synergize to activate
Kupffer cells and modulate the fibrogenic response via tumor necrosis factor
alpha, reduced glutathione, and transforming growth factor beta-dependent
mechanisms. Hepatology 2008, 48:2027–2039.
4. Cheng K, Yang N, Mahato RI: TGF-beta1 gene silencing for treating liver
fibrosis. Mol Pharm 2009, 6:772–779.
5. Kong L, Ren W, Li W, Zhao S, Mi H, Wang R, Zhang Y, Wu W, Nan Y, Yu J:
Activation of peroxisome proliferator activated receptor alpha ameliorates
ethanol induced hepatic steatohepatitis in mice. Lipids Health Dis 2011,
10:246.
6. Brattin WJ, Glende EA Jr, Recknage lRO: Pathological mechanisms in
carbon tetracholoride hepatotoxicity. J Free Radic Biol Med 1985, 1:27–38.
7. Pan X, Hussain FN, Iqbal J, Feuerman MH, Hussain MM: Inhibiting
Proteasomal Degradation of Microsomal Triglyceride Transfer Protein
Prevents CCl4-induced Steatosis. J Biol Chem 2007, 282:17078–17089.
8. Ismail RS, El-Megeid AA, Abdel-Moemin AR: Carbon tetrachloride-induced
liver disease in rats: the potential effect of supplement oils with vitamins
E and C on the nutritional status. Ger Med Sci 2009, 7:Doc05.
9. Hall PD, Plummer JL, Ilsley AH, Cousins MJ: Hepatic fibrosis and cirrhosis
after chronic administration of alcohol and “low-dose” carbon
tetrachloride vapor in the rat. Hepatology 1991, 13:815–819.
10. Povero D, Busletta C, Novo E, di Bonzo LV, Cannito S, Paternostro C, Parola
M: Liver fibrosis: a dynamic and potentially reversible process. Histol
Histopathol 2010, 25:1075–1091.
11. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N, Toda K,
Kaneko T, Horie Y, Han JY, Kato S, Shimoda M, Oike Y, Tomizawa M, Makino S,
Ohkura T, Saito H, Kumagai N, Nagata H, Ishii H, Hibi T: Tumour necrosis factor α
signalling through activation of Kupffer cells plays an essential role in liver
fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006, 55:415–424.
12. Seth D, Gorrell MD, Cordoba S, McCaughan GW, Haber PS: Intrahepatic
gene expression in human alcoholic hepatitis. J Hepatol 2006, 45:306–320.
13. Pritchett J, Harvey E, Athwal V, Berry A, Rowe C, Oakley F, Moles A, Mann
DA, Bobola N, Sharrocks AD, Thomson BJ, Zaitoun AM, Irving WL, Guha IN,
Hanley NA, Hanley KP: Osteopontin is a novel downstream target of
SOX9 with diagnostic implications for progression of liver fibrosis in
humans. Hepatology 2012, 56:1108–1116.
14. Tokairin T, Nishikawa Y, Watanabe H, Doi Y, Omori Y, Yoshioka T, Yamamoto
Y, Yoshida M, Nishimura T, Li Q, Arai H, Ishida A, Takada G, Enomoto K:
Osteopontin expression in the liver with severe perisinusoidal fibrosis:
Autopsy case of Down syndrome with transient myeloproliferative
disorder. Pathol Int 2008, 58:64–68.
15. Urtasun R, Lopategi A, George J, Leung TM, Lu Y, Wang X, Ge X, Fiel MI,
Nieto N: Osteopontin, an oxidant stress sensitive cytokine, up-regulates
collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB
signaling. Hepatology 2012, 55:594–608.
16. Lang Q, Liu Q, Xu N, Qian KL, Qi JH, Sun YC, Xiao L, Shi XF: The antifibrotic
effects of TGF-β1 siRNA on hepatic fibrosis in rats. Biochem Biophys Res
Commun 2011, 409:448–453.
17. Ehnert S, Baur J, Schmitt A, Neumaier M, Lucke M, Dooley S, Vester H, Wildemann
B, Stöckle U, Nussler AK: TGF-β1 as possible link between loss of bone mineral
density and chronic inflammation. PLoS One 2010, 5:e14073.
18. Huang L, Wei MF, Feng JX: Abnormal activation of OPN inflammation
pathway in livers of children with biliary atresia and relationship to
hepatic fibrosis. Eur J Pediatr Surg 2008, 18:224–229.
19. Moschen AR, Gerner R, Schroll A, Fritz T, Kaser A, Tilg H: A Key Role for
Pre-B cell Colony-Enhancing Factor in Experimental Hepatitis. Hepatology
2011, 54:675–686.
20. Ognjanovic S: Genomic organization of the gene coding for human
pre-B-cell colony enhancing factor and expression in human fetal
membranes. J Mol Endocrinol 2001, 26:107–117.
21. Adya R, Tan BK, Punn A, Chen J, Randeva HS: Visfatin induces human
endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt
signalling pathways: novel insights into visfatin-induced angiogenesis.
Cardiovasc Res 2008, 78:356–365.
22. Ikeda K, Wakahara T, Wang YQ, Kadoya H, Kawada N, Kaneda K: In vitro
migratory potential of rat quiescent hepatic stellate cells and its
augmentation by cell activation. Hepatology 1999, 29:1760–1767.
23. Zhou X, Hovell CJ, Pawley S, Hutchings MI, Arthur MJ, Iredale JP, Benyon RC:
Expression of matrix metalloproteinase-2 and −14 persists during earlyresolution of experimental liver fibrosis and might contribute to
fibrolysis. Liver Int 2004, 24:492–501.
24. Galli A, Svegliati-Baroni G, Ceni E, Milani S, Ridolfi F, Salzano R, Tarocchi M,
Grappone C, Pellegrini G, Benedetti A, Surrenti C, Casini A: Oxidative stress
stimulates proliferation and invasiveness of hepatic stellate cells via a
MMP2-mediated mechanism. Hepatology 2005, 41:1074–1084.
25. Parola M, Robino G: Oxidative stress-related molecules and liver fibrosis.
J Hepatol 2001, 35:297–306.
26. Han YP, Yan C, Zhou L, Qin L, Tsukamoto H: A Matrix Metalloproteinase-9
Activation Cascade by Hepatic Stellate Cells in Trans-differentiation in the
Three-dimensional Extracellular Matrix. J Biol Chem 2007, 282:12928–12939.
27. Perng DW, Chang KT, Su KC, Wu YC, Chen CS, Hsu WH, Tsai CM, Lee YC:
Matrix metalloprotease-9 induces transforming growth factor-β(1)
production in airway epithelium via activation of epidermal growth
factor receptors. Life Sci 2011, 89:204–212.
28. Zhu X, Wang L, Zhang B, Li J, Dou X, Zhao RC: TGF-beta1-induced PI3K/
Akt/NF-kappaB/MMP9 signalling pathway is activated in Philadelphia
chromosome-positive chronic myeloid leukaemia hemangioblasts.
J Biochem 2011, 149:405–414.
29. Thakur V, Pritchard MT, McMullen MR, Nagy LE: Adiponectin normalizes
LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic
ethanol feeding. Am J Physiol 2006, 290:G998–1007.
30. Tomita K, Oike Y, Teratani T, Taguchi T, Noguchi M, Suzuki T, Mizutani A,
Yokoyama H, Irie R, Sumimoto H, Takayanagi A, Miyashita K, Akao M, Tabata
M, Tamiya G, Ohkura T, Hibi T: Hepatic adipoR2 signaling plays a
protective role against progression of nonalcoholic steatohepatitis in
mice. Hepatology 2008, 48:458–473.
31. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA: The roles of leptin
and adiponectin: a novel paradigm in adipocytokine regulation of liver
fibrosis and stellate cell biology. Am J Pathol 2005, 166:1655–1669.
32. Wu CW, Chu ES, Lam CN, Cheng AS, Lee CW, Wong VW, Sung JJ, Yu J:
PPARgamma is essential for protection against nonalcoholic
steatohepatitis. Gene Ther 2010, 17:790–798.
33. Mandal P, Pritchard MT, Nagy LE: Anti-inflammatory pathways and
alcoholic liver disease: role of an adiponectin/interleukin-10/heme
oxygenase-1 pathway. World J Gastroenterol 2010, 16:1330–1336.
34. Zheng WD, Zhang LJ, Shi MN, Chen ZX, Chen YX, Huang YH, Wang XZ:
Expression of matrix metalloproteinase-2 and tissue inhibitor of
metalloproteinase-1 in hepatic stellate cells during rat hepatic fibrosis and its
intervention by IL-10. World J Gastroenterol 2005, 11:1753–1758.
35. Zhang LJ, Chen YX, Chen ZX, Huang YH, Yu JP, Wang XZ: Effect of
interleukin-10 and platelet-derived growth factor on expressions of
matrix metalloproteinases-2 and tissue inhibitor of metalloproteinases-1
in rat fibrotic liver and cultured hepatic stellate cells. World J
Gastroenterol 2004, 10:2574–2579.
36. Zhang LJ, Zheng WD, Chen YX, Huang YH, Chen ZX, Zhang SJ, Shi MN,
Wang XZ: Antifibrotic effects of interleukin-10 on experimental hepatic
fibrosis. Hepatogastroenterology 2007, 54:2092–2098.
37. Zhang LJ, Yu JP, Li D, Huang YH, Chen ZX, Wang XZ: Effects of cytokines
on carbon tetrachloride-induced hepatic fibrogenesis in rats. World J
Gastroenterol 2004, 10:77–81.
38. Kovalovich K, DeAngelis RA, Li W, Furth EE, Ciliberto G, Taub R: Increased
toxin-induced liver injury and fibrosis in interleukin-6-deficient mice.
Hepatology 2000, 31:149–159.
39. Wang XZ, Zhang SJ, Chen YX, Chen ZX, Huang YH, Zhang LJ: Effects of
platelet-derived growth factor and interleukin-10 on Fas/Fas-ligand and
Bcl-2/Bax mRNA expression in rat hepatic stellate cells in vitro. World J
Gastroenterol 2004, 10:2706–2710.
40. Gómez-Hurtado I, Zapater P, Bellot P, Pascual S, Pérez-Mateo M, Such J,
Francés R: Interleukin-10-Mediated Heme Oxygenase 1-Induced
Underlying Mechanism in Inflammatory Down-Regulation by Norfloxacin
in Cirrhosis. Hepatology 2011, 53:935–944.
41. Drechsler Y, Dolganiuc A, Norkina O, Romics L, Li W, Kodys K, Bach FH,
Mandrekar P, Szabo G: Heme oxygenase-1 mediates the anti-inflammatory
effects of acute alcohol on IL-10 induction involving p38 MAPK activation
in monocytes. J Immunol 2006, 177:2592–2600.
42. Wang RQ, Nan YM, Wu WJ, Kong LB, Han F, Zhao SX, Kong L, Yu J:
Induction of heme oxygenase-1 protects against nutritional fibrosing
steatohepatitis in mice. Lipids Health Dis 2011, 10:31.
43. Dominguez M, Rincón D, Abraldes JG, Miquel R, Colmenero J, Bellot P,
García-Pagán JC, Fernández R, Moreno M, Bañares R, Arroyo V, Caballería J,
Nan et al. Lipids in Health and Disease 2013, 12:11 Page 10 of 10
http://www.lipidworld.com/content/12/1/11Ginès P, Bataller R: A new scoring system for prognostic stratification of
patients with alcoholic hepatitis. Am J Gastroenterol 2008, 103:2747–2756.
44. The Chinese National Workshop on Fatty Liver and Alcoholic Liver Disease
for the Chinese Liver Disease Association: Guideline for management of
alcoholic liver disease: a update and revised edition. Zhonghua
Ganzangbing Zazhi 2010, 18:167–170.
doi:10.1186/1476-511X-12-11
Cite this article as: Nan et al.: Activation of peroxisome proliferator
activated receptor alpha ameliorates ethanol mediated liver fibrosis in
mice. Lipids in Health and Disease 2013 12:11.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
